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Background: Asthma, chronic obstructive pulmonary disease (COPD), and asthma–COPD 
overlap (ACO) are complex and heterogeneous diseases that share clinical characteristics 
(phenotypes) and molecular mechanisms (endotypes). Whilst physicians make clinical deci-
sions on diagnostic groups, for some such as ACO there is no commonly accepted criteria. 
An alternative approach is to evaluate phenotypes and endotypes that are considered to 
respond well to a specific type of treatment (“treatable traits”) rather than diagnostic labels.
Purpose: The prospective, longitudinal, and observational TRAIT study will evaluate 
disease characteristics, including both phenotypes and endotypes, in relation to the presenta-
tion of obstructive respiratory disease characteristics in patients diagnosed with asthma, 
COPD, or ACO in Japan, with the aim of further understanding the clinical benefit of 
a treatable traits-based approach.
Patients and Methods: A total of 1500 participants will be enrolled into three cohorts 
according to their treating physician’s diagnosis of asthma, COPD, or ACO at screening. 
Part 1 of the study will involve cross-sectional phenotyping and endotyping at study 
enrollment. Part 2 of the study will evaluate the progression of clinical characteristics, 
biomarker profiles, and treatment over a 3-year follow-up period. The follow-up will involve 
three annual study visits and three telephone calls scheduled at 6-month intervals. A substudy 
involving 50 participants from the asthma cohort (in which the ratio will be approximately 
1:1 including 25 participants with a smoking history of ≥10 pack-years and 25 participants 
with no smoking history), 100 participants from the ACO cohort, and 100 participants from 
the COPD cohort will evaluate disease phenotypes using inspiratory and expiratory com-
puted tomography scans.
Conclusion: TRAIT will describe clinical characteristics of patients with obstructive 
respiratory diseases to better understand potential differences and similarities between 
clinical diagnoses, which will support the improvement of personalized treatment strategies.
Keywords: ACO, asthma, COPD, personalized medicine, biomarkers, treatable traits
Plain Language Summary
Why Was the Study Done?
Asthma and chronic obstructive pulmonary disease (COPD) are two of the most common 
obstructive respiratory diseases. There are also patients in whom the features of asthma and 
COPD overlap and they are diagnosed with asthma–COPD overlap. These diseases are 
complex as they share many similar clinical and biological characteristics, often making 
diagnosis difficult in a precise or appropriate manner. This study looks at how we can 
describe the characteristics of patients with asthma, COPD, or ACO and how such 
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characteristics change over time, to provide clinicians with an 
understanding of how they may assess and treat individual 
patients.
What Did Researchers Do/Find?
The study involves two parts. The first part aims to under-
stand treatment decisions by looking at characteristics such as 
symptoms, comorbidities, quality of life, and biomarkers (includ-
ing blood markers and imaging) among patients diagnosed with 
asthma, COPD, or ACO in Japan. The second part will look at 
how these characteristics, treatment, and disease severity change 
over a 3-year period.
What Do These Results Mean?
The study will increase understanding of the clinical charac-
teristics associated with asthma, COPD, and ACO, with the aim 
of personalizing treatment to the individual patient to improve 
disease management.
Introduction
Asthma and chronic obstructive pulmonary disease 
(COPD) are two of the most common obstructive respira-
tory diseases worldwide.1 These diseases have 
a significant socioeconomic burden associated with them 
and are important drivers of impairment in health-related 
quality of life.1–4 There is a large proportion of patients 
who present with overlapping disease characteristics and 
who fulfil the criteria for, and are therefore subsequently 
diagnosed with, asthma–COPD overlap (ACO).5 To pro-
vide context, in Japan, a recent study has reported that up 
to 30% of patients who presented with persistent airflow 
limitation shared clinical features of both asthma and 
COPD, and therefore fulfilled the diagnostic criteria for 
ACO.6 A precise definition of ACO has not yet been 
agreed worldwide and a review showed 11 different defi-
nitions in current use, leading to disagreement about the 
clinical characteristics.5 Whilst multiple criteria are used 
for defining ACO, there is very little concordance between 
patients classified using different methods.7 In 2018, the 
Japanese Respiratory Society (JRS) published guidelines 
for the management of ACO, as well as the first unified 
diagnostic criteria for ACO in Japan.6,8,9 ACO was defined 
as the coexistence of asthma features and COPD features 
in patients with chronic airway obstruction, with 
a recommendation to treat with inhaled corticosteroids 
(ICS) in the presence of asthma features in additional to 
bronchodilators.8
There has been difficulty in reaching a consensus regard-
ing ACO due to the fact that both COPD and asthma are 
clinically and biologically complex diseases, therefore over-
lap between them increases that complexity.10,11 The typical 
characteristics are still under discussion, and differences 
exist between countries. They exhibit significant heteroge-
neity, sharing clinical characteristics (phenotypes) and bio-
logical mechanisms (endotypes) that are not mutually 
exclusive.10–12 These characteristics or traits may be present 
in isolation or in combination and can change over time, due 
to progression of the disease or as a consequence of disease 
management.13 Despite the heterogenous nature of these 
diseases, current treatment guidelines recommend 
a stepwise approach to disease management based on 
a primary diagnosis of COPD or asthma, rather than the 
treatable trait such as airflow obstruction or eosinophilic 
inflammation.14,15 Guidance on treatment for patients diag-
nosed with ACO is less clear, whereby Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guidelines no 
longer refer to ACO, and instead emphasize that asthma and 
COPD are different disorders that may share some common 
traits and clinical features.15 When these disorders coexist, 
GOLD proposes initial treatment for asthma using 
a stepwise approach until further investigations are 
performed.5,8,15 It is important to note that in the JRS guide-
lines, the patients should meet the criteria for COPD as well 
as the criteria for asthma with COPD, reflecting the fact that 
patients with ACO should all have COPD and that the 
asthma component is in addition to COPD.8 In clinical 
practice, physicians are increasingly using a personalized 
approach to manage patients with obstructive respiratory 
diseases, with treatment decisions based on clinical charac-
teristics rather than diagnostic labels.15–17 This approach 
recognizes clinical characteristics that have been shown to 
or are considered to respond well to a specific type of 
treatment, referred to as “treatable traits.”
The body of evidence around the overlapping clinical 
phenotypes, underlying biological mechanisms and manage-
ment of patients across the spectrum of obstructive respiratory 
diseases is growing.18–22 However, there remains a need for 
additional large observational studies to fully characterize 
treatable traits. This two-part study will initially evaluate 
clinical characteristics, biomarker profiles, and treatment in 
patients diagnosed with asthma, COPD, or ACO in Japan, 
with the aim of better understanding treatment decisions and 
will go on to evaluate the progression of clinical characteris-
tics, biomarker profiles, and treatment evolution over a 3-year 
longitudinal follow-up period in a Japanese population.
Objectives of the Study Protocol
The primary objective of the TRAIT study is to describe the 
characteristics of participants with obstructive respiratory 
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diseases categorized on the basis of clinical evaluation and 
judgment (Part 1). Secondary objectives are to evaluate the 
progression of clinical characteristics over time, characterize 
biomarkers and profiles over time, and understand how 
physicians assess and treat patients with obstructive respira-
tory disease in clinical practice (Part 2).
Materials and Methods
Study Setting and Design
The TRAIT study (ID212311; JapicCTI-194844)23 is 
a prospective, longitudinal, observational cohort study, 
consisting of two parts (Figure 1). Participants will be 
enrolled into three cohorts based on a physician’s diagno-
sis of asthma, COPD, or ACO at screening.
Part 1 of the study will involve cross-sectional pheno-
typing and endotyping to identify clinical and laboratory 
traits in participants with obstructive respiratory disease at 
study enrollment (Visit 1); Part 2 will evaluate the pro-
gression of clinical traits, biomarker profiles, and treat-
ment over a 3-year, longitudinal follow-up period to 
identify which have the greatest predictive value for out-
come and utility in clinical decision making. The follow- 
up period will involve three annual study visits and three 
telephone calls to participants, scheduled at 6-month inter-
vals. Evaluable participants for Part 1 of the study will be 
all enrolled participants who complete Visit 1 and those 
for Part 2 will be all enrolled participants who complete 
Part 1 and at least one study visit in Part 2.
In addition, a phenotyping lung imaging substudy will be 
conducted to evaluate disease phenotypes through two low- 
dose high-resolution computed tomography scans (inspira-
tory and expiratory), to be performed at Visit 1 or any time 
in this study. A target of 50 participants from the asthma 
cohort (in which the ratio will be approximately 1:1 includ-
ing 25 participants with a smoking history of ≥10 pack-years 
and 25 participants with no smoking history), 100 partici-
pants from the ACO cohort, and 100 participants from the 
COPD cohort will be enrolled for the substudy. Participants 
will only be able to enter the substudy if they are enrolled at 
selected study sites with access to appropriate equipment. 
Additionally, all participants for the substudy will be 
required to complete at least Part 1 of this study. 
A steering committee including external experts and 
GlaxoSmithKline (GSK) guided the study design, and will 
guide the conduct, analysis, and interpretation.
Study Population
Participants (male or female) 40–80 years of age who are 
capable of giving signed, informed consent will be 
included into one of three cohorts based on the criteria 
outlined in Table 1.
In the asthma cohort at least 50% of participants must be 
using an ICS/long-acting β2-agonist (LABA) at screening. In 
the ACO and COPD cohorts, at least 75% of participants must 
have a post-bronchodilator forced expiratory volume in 
1 second/ forced vital capacity (FEV1/FVC) less than 0.7 at 
Visit 1, and at least 50% of participants must have experienced 
an event in the 24 months prior to screening, when an event is 
defined as symptoms of respiratory tract infection requiring 
antibiotics and/or systemic corticosteroids, a moderate-to- 
severe exacerbation, or an asthma attack. The ACO cohort 
will include participants who meet guideline-defined ACO, 
COPD with features of asthma, or asthma with features of 
COPD.9 Whilst participants may be enrolled into this study 
with a physician’s diagnosis of COPD or ACO, and not meet 
the spirometric criteria for these conditions, the adaptive inclu-
sion criteria will ensure that a substantial proportion of the 
study population meet the spirometric criterion of post- 
bronchodilator FEV1/FVC less than 0.7.17 Screening data 
will be monitored to ensure the adaptive inclusion criteria 
Figure 1 TRAIT study design. 
Abbreviations: FU, follow-up; Tel, telephone.
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are met. Other participants must meet the definition of unstable 
ACO/COPD. A participant with unstable ACO/COPD in the 
context of this study is defined as one who has experienced at 
least one of the following events in the 24 months prior to or at 
Visit 1: shortness of breath despite using ICS/LABA medica-
tion, symptoms (such as cough, sputum, or shortness of 
breath), and/or a worsening of symptoms despite using long- 
acting muscarinic antagonist (LAMA), LAMA/LABA, or 
ICS/LAMA/LABA medication. No study-specific treatments 
will be administered; participants will continue to use medica-
tions prescribed by their regular treating physician and will 
continue to visit their regular treating physician for their 
healthcare. Data on medications taken for respiratory diseases 
will be collected as part of the study; however, any changes to 
medications during the study will be at the discretion of the 
participant’s regular treating physician.
Recruitment
The investigators in each participating site are responsible 
for the recruitment of eligible patients and for following 
them up for three years until the end of the study. 
Enrollment will be closed when the number of patients 
reaches the target in each cohort. The adaptive criteria may 
restrict recruitment of patients in three categories: patients 
with asthma treated with ICS only (without LABA); 
patients with ACO/COPD with FEV1/FVC ≥0.7 at Visit 
1; patients with ACO/COPD who experienced no acute 
events (defined above) for 2 years.
Results
The primary endpoint will be assessed in Part 1 of the 
study and is the proportion of participants presenting with 
different combinations of clinical characteristics (Table 2). 
Secondary endpoints (Table 2) will be assessed during 
Part 2 of the study and include clinical characteristics, 
biomarker measurements, and physician-assessed para-
meters. The endpoints of the phenotyping lung imaging 
substudy will include airway wall thickness, lung density, 
total lung capacity, and residual volume.
Assessments
The schedule for the assessment of the disease-related 
variables is shown in Table 3.








A physician’s diagnosis of ACO, and be a regular user of LAMA, and/or LABA, and/or ICS maintenance medication
COPD 
Cohort
A physician’s diagnosis of COPD, and be a regular user of LAMA, and/or LABA maintenance medication regardless of concomitant 
ICS use
Exclusion Criteria
Major lung surgery (eg, lung reduction, lobectomy, or lung transplant)
Known history of significant inflammatory disease other than COPD (eg, rheumatoid arthritis or lupus) (ACO and COPD 
Cohorts only)
Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on participant 
safety
Cancer diagnosis within the last 5 years (participants in remission for ≥5 years are eligible)
Current primary diagnosis of diffuse pan-bronchiolitis, or a primary diagnosis of bronchiectasis or pulmonary fibrosis
Diagnosis of chronic bronchitis or pulmonary emphysema and demonstrate no spirometric evidence of obstructive lung disease
Participant is currently participating in another study involving investigational study treatment intervention
Participant is unable to perform spirometry
Notes: *The ACO cohort will include participants with guideline-defined ACO, COPD with features of asthma, or asthma with features of COPD. 
Abbreviations: ACO, asthma–chronic obstructive pulmonary disease overlap; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long- 
acting β2-agonist; LAMA, long-acting muscarinic antagonist.
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Japanese-translated versions of the following question-
naires will be completed at the start of each on-site study 
visit: A modified version of the COPD Assessment Test: 
Chronic Airways Assessment Test (CAAT),24 Asthma 
Control Questionnaire (ACQ-5),25 and the St George’s 
Respiratory Questionnaire (SGRQ).26 A summary of 
these questionnaires is shown in Table 4. A Japanese- 
translated version of the modified Medical Research 
Council (mMRC) Dyspnea Scale27 will be completed by 
investigators and used to measure baseline functional 
Table 2 Endpoints of the TRAIT Study
Primary endpoint (Part 1)
The proportion of participants presenting with combinations of clinical characteristics seen at Visit 1:
● Participants with a pre-bronchodilator FEV1 ≥30% and <85%, airway reversibilitya, at least one eventb in the 24 months prior to Visit 1, an 
ACQ-5 score ≥1.5
● Participants with a smoking historyc, post-bronchodilator FEV1/FVC <0.7, at least one eventb in the 24 months prior to Visit 1, a CAAT4 score 
≥10, and peripheral blood EOS ≥100 cells/μL
Secondary endpoints (Part 1 and Part 2)
Clinical characteristics
● The proportion of participants presenting with combinations of clinical characteristics at each visit
● The mean annual rate of eventsd
● The mean annual rate of moderate and severe exacerbationse
● Pre- and post-bronchodilator FEV1, FVC, and FEV1/FVC ratio at each visit
● Airway reversibility (increase from pre-bronchodilator FEV1 of ≥12% and 200 mL) at each visit
● CAAT, ACQ-5, SGRQ, mMRC dyspnea scale score at each visit
● Proportion of participants experiencing a clinically important deterioration in their obstructive respiratory disease per yearf
● Time to lung cancer-related, respiratory-related but not lung cancer-related, and all-cause death
Biomarkers
● DLCO and FeNO at each visit
● CT scans for evaluating the degree of airways disease and emphysema
● Total and differential white blood cell count at each visit
● Proportion of participants with peripheral blood EOS count ≥100 cell/μL at each visit
● Levels of blood biomarkers* associated with respiratory disease progression and outcomes
Physician-assessed parameters
● Medical history and comorbidities at each visit
● The proportion of participants whose physician’s diagnosis of asthma, COPD or ACO changes during the study
● Respiratory medications and nondrug therapies received by participants
● Type of modifications to maintenance medication for asthma/ACO/COPD during the study
● The proportion of participants who meet the GINA, 2018 definition of asthma at each visit
● The proportion of participants who meet the JRS, 2018 definition of ACO at each visit
● The proportion of participants who meet the GOLD, 2019 definition of COPD at each visit: having dyspnea, chronic cough, or sputum 
production, a history of exposure to risk factors, and persistent airflow limitation (post-bronchodilator FEV1/FVC <0.7)
● Mean annual rate of respiratory-related HRU
● Mean annual rate of respiratory-related and all-cause hospitalizations
Notes: *Blood markers assessed will include total and differential white blood cell count; serum high-sensitivity C-reactive protein (hsCRP); serum IgE; plasma fibrinogen; 
serum soluble form of receptor for advanced glycation end products (sRAGE); lung matrix turnover markers; inflammatory cytokines associated with disease activity such as 
interleukin (IL)-17, IL-33, or chemokine ligand (CXCL)-10. aAirway reversibility is defined as follows; post-bronchodilator spirometry values show the change in FEV1 ≥12 as 
a percentage on pre-bronchodilator values in combination with increase in absolute FEV1 ≥200 mL compared with pre-bronchodilator values. 
bEvent includes: symptoms of 
respiratory tract infection requiring antibiotics and/or systemic corticosteroids, moderate-to-severe asthma/ACO/COPD exacerbation, and asthma attacks requiring 
additional short-acting β2-agonist (SABA) treatment or SMART treatment. cParticipants with a smoking history are defined as those with a smoking history of ≥10 pack- 
years. dEvent for the mean annual rate includes: symptoms of respiratory tract infection requiring antibiotics and/or systemic corticosteroids and moderate-to-severe 
asthma/ACO/COPD exacerbation. eA moderate exacerbation is defined as a worsening of asthma/ACO/COPD that requires treatment with systemic corticosteroids and/ 
or antibiotics. A severe exacerbation is defined as a worsening of asthma/ACO/COPD that requires hospitalization. fA clinically important deterioration is a composite 
measure including the worsening of key clinical features: lung function, symptoms, and exacerbation events. 
Abbreviations: ACO, asthma–COPD overlap; ACQ-5, Asthma Control Questionnaire-5; CAAT, Chronic Airways Assessment Test; COPD, chronic obstructive pulmonary 
disease; DLCO, diffusing capacity of the lungs for carbon monoxide; EOS, eosinophil; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; GINA, Global Initiative for Asthma; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HRU, healthcare resource utilization; JRS, 
Japanese Respiratory Society; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire.
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Table 3 Schedule for Assessment of Disease-Related Variables
Variables Visits
SCR Visit 1 Visit 2 Visit 3 Visit 4
Demography (age/gender) X
Height, weight, and BMI X X X X
Vital signs X X X X X
Medical history X X
Comorbidities X X X X X
Diagnosis of and medication for asthma/ACO/COPD X X X X X
Smoking status X X X X
Spirometry testing X X X X
Collect narratives of any lung CT scans* X X X X
Record healthcare resource utilization X X X
Blood sampling for biomarker analysis† X X X X
DLCO and FeNO testing‡ X X X X
CAAT, ACQ-5, SGRQ, and mMRC Dyspnea Scale X X X X
Record occurrence of events§ X X X X
Notes: *CT scans not required as part of the main study. If a participant has had any lung CT scans performed in the year prior to entering the study or any lung CT scans 
performed as part of routine clinical management during the study, then the radiologist’s or pulmonologist’s narrative will be collected. †Blood samples for analysis of 
emerging biomarkers will only be collected at Visit 1 and Visit 4. Blood samples for analysis of all other biomarkers will be collected at all study visits. ‡DLCO testing and 
FeNO testing are only required to be performed at study sites that have access to equipment. §Respiratory tract infection requiring antibiotics and/or systemic 
corticosteroid, exacerbation, asthma attacks, serious adverse events. 
Abbreviations: ACQ-5, Asthma Control Questionnaire-5; ACO, asthma–COPD overlap; BMI, body mass index; CAAT, Chronic Airways Assessment Test; COPD. Chronic 
obstructive pulmonary disease; CT, computerized tomography; DLCO, diffusing capacity of the lungs for carbon monoxide; FeNO, fractional exhaled nitric oxide; mMRC, 
modified Medical Research Council; SCR, screening; SGRQ, St George’s Respiratory Questionnaire.
Table 4 Tools to Assess Symptoms in the TRAIT Study
Description Scoring
Patient-completed questionnaires
CAAT24 An 8-item questionnaire, which is a modified version of the 
COPD Assessment Test (CAT)39,40 with an adaptation of 
introductory sentence referring to “chronic airway disease” 
instead of COPD. 
This patient-completed questionnaire covers symptoms such as 
cough, phlegm, chest tightness, and breathlessness, and disease 
impacts including physical activity, confidence, sleep, and energy
Scores range from 0 to 40, with higher scores indicating a poorer 
chronic airway disease health status. 
Items are scored on a 6-point response scale, with a score of 0 
representing the patient not experiencing the symptom or the 
impact at all and a score of 5 representing a maximal symptom or 
impact.
ACQ-525 A 5-item questionnaire for assessing asthma control, completed 
by the patient based on recall of the past week. Questions relate 
to asthma symptoms
Each item is scored on a 
7-point scale (0=no impairment; 6=maximum impairment). The 
items are equally weighted and the overall score is the mean of 
the seven items; between 0 (well controlled) and 6 (extremely 
poorly controlled)
SGRQ26 A 76-item questionnaire used to measure health status in patients 
with asthma and COPD
The total score is based on three domain scores: symptoms, 
activity, and impacts (on daily life). A decrease in score indicates 





A 5-point scale used to measure baseline functional impairment 
due to dyspnea attributable to respiratory disease by considering 
how daily activities such as walking and climbing stairs are 
impacted by breathlessness
This 5-point scale ranges from 0=breathless only with strenuous 
exercise to 4=too breathless to leave the house
Abbreviations: ACQ-5, Asthma Control Questionnaire-5; CAAT, Chronic Airways Assessment Test; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary 
disease; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire.
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impairment due to dyspnea attributable to respiratory dis-
ease (Table 4).
All adverse events will be monitored throughout the 
study and all serious adverse events will be recorded in the 
electronic case report form.
Sample Size
An estimated 2000 participants were intended to be 
screened to enroll approximately 1800 participants into 
the study. The rationale for the sample size is that when 
the proportion of participants with any individual clinical 
characteristic is 50%, the maximum width of the 95% 
confidence interval (CI) is 8.2%. However, due to the 
COVID-19 pandemic, the original sample size was revised 
to ensure a balance between scientific value and study 
feasibility. A total of 1500 participants will now be 
enrolled across approximately 80 sites, with 500 partici-
pants in each of the asthma, COPD, and ACO, cohorts. 
The maximum width of the 95% CI marginally increased 
to 8.9% due to the reduction of sample size.
Statistical Analyses
This is a descriptive study that is not powered to detect 
differences and no formal statistical hypothesis testing will 
be performed for any of the endpoints. A cross-sectional 
analysis will be performed on data from Part 1 of the study 
when the study is fully enrolled. The primary endpoints 
are the proportion of participants presenting with combi-
nations of clinical characteristics; therefore, the percentage 
and 95% CI will be shown for specific combinations of 
characteristics. Regarding other endpoints, summary sta-
tistics will be presented. Data from Part 2 will be analyzed 
when all participants have completed the study. All end-
points will be explored within each of the asthma, COPD, 
and ACO cohorts. The change in clinical characteristics 
over time will be shown, which includes data from pul-
monary function tests, questionnaires, and biomarkers.
Discussion
The TRAIT study will evaluate characteristics or traits, 
including clinical characteristics (phenotypes) and biologi-
cal mechanisms (endotypes) in patients with asthma, 
COPD, and ACO in Japan, using a standard methodology 
across all three groups to investigate the different charac-
teristics and potential clinical benefit of a treatable traits- 
based approach to patient characterization.
TRAIT will provide further data to compare disease 
characteristics in Japan to data from large multicenter 
observational studies, including western cohorts and cohorts 
in Japan (Hokkaido, Takahata, Kyoto), which have been 
conducted with the aim of defining clinically relevant sub-
types of COPD and asthma, as well as novel biomarkers and 
predictive markers of progression.13,18–22,24,28–30 These 
include the ECLIPSE, COPDGene, and SPIROMICS studies 
in COPD, and the European U-BIOPRED study in 
asthma.13,18–22,24,31–33 However, whilst these studies have 
provided valuable insights into patient characteristics, bio-
markers, and phenotypes in asthma and COPD populations, 
detailed characterization of ACO in these cohorts is limited 
due to their inclusion criteria. Individuals with ACO are more 
commonly excluded from studies that require a diagnosis of 
asthma or COPD, in part due to the lack of definitive inclu-
sion criteria.9 The ACO registry and the NOVELTY study, 
however, did include individuals with ACO as part of their 
inclusion criteria,24,34 but more is needed to clarify the 
responsible molecular pathways and identify possible bio-
markers for optimal therapeutic intervention in patients with 
ACO.35 This study will explore a different approach to 
classifying patients based on diagnostic labels, because it 
will explore the characterization of patients across the spec-
trum of obstructive respiratory disease using a treatable-traits 
approach.
Strengths
A major strength of the TRAIT study design is that it is 
a large prospective study across multiple different sites, 
enabling the longitudinal observation of obstructive lung 
disease in Japanese clinical practice. Another strength is 
the comprehensive assessment of clinical characteristics, 
biomarkers, and physician-assessed parameters in a large 
patient population across each of the three diagnostic 
cohorts. In this study, not only will disease-related vari-
ables be assessed at an initial baseline visit, but also long-
itudinally over a 3-year period. This will enable the 
investigators to evaluate if clinical variables, such as 
lung function, exacerbations, or quality of life change 
within the cohorts over time. In addition, the longitudinal 
collection of a wide variety of biomarkers, including lung 
imaging, to allow detection of any changes over time, with 
the potential that these biomarkers could be used as indi-
cators of disease progression. Finally, the adaptive inclu-
sion criteria allow for the recruitment of patients 
prescribed varying medications, in real-world clinical set-
tings in Japan. This enables the observation of patients 
with relatively severe disease who require further 
treatment.
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Some limitations of the TRAIT study should also be con-
sidered. First, the classification of patients into diagnostic 
groups will be made by physicians, using their own judg-
ment, but whilst this may appear to be a limitation it is 
also a strength because it will give insights into the criteria 
used by clinicians in routine practice to categorize patients 
with airflow limitation. To accommodate this pragmatic 
approach to recruitment by diagnostic groups, an adaptive 
approach to recruitment is needed, for example to limit 
patients recruited to the ACO and COPD group who do 
not meet spirometric criteria for COPD. Due to the inclu-
sion criteria, participants in the asthma cohort may experi-
ence systemic inflammatory diseases that could make it 
difficult to identify pathogenesis and pose a challenge 
when interpreting biomarkers. However, this may be miti-
gated by stratifying data by comorbidities during analysis. 
The size of the cohorts is relatively small, particularly for 
the substudy analysis of the high-resolution computed 
tomography scans, which will only involve participants 
enrolled at a study site that has access to appropriate 
equipment. The observational nature of the study also 
introduces limitations; participants may leave the study 
for different reasons and dropout rates may be different 
between the cohorts. The participants who remain in the 
study may have different characteristics to those who drop 
out. In addition, since this study will be conducted in 
Japan, the outcomes obtained may not necessarily be gen-
eralizable to other study populations in other countries. 
Finally, there may be a study effect in that the physicians’ 
management of the patients may change as a result of 
joining the study.
Clinical Implications
Physicians worldwide, including in Japan, are increasingly 
choosing strategies based on the treatable-traits approach by 
considering the patients phenotype and endotype, rather 
than assigning diagnostic labels to patients and placing 
them within a treatment and diagnostic silo.13,16 This 
approach is reflected in the GOLD guidelines, which no 
longer refer to ACO, and emphasize that COPD and asthma 
are different disorders with common traits and clinical 
features that may be shared. However, to fully utilize this 
approach, potential treatable traits across the spectrum of 
obstructive respiratory diseases need to be fully character-
ized. Previous studies have demonstrated the ability to 
assess treatable traits in asthma and COPD, which can 
subsequently be targeted using a personalized-medicine 
approach to improve health-related quality of life, disease 
control, and reduce healthcare visits.36–38 Results from this 
study will significantly expand this knowledge base of 
treatable traits associated with asthma, COPD, and ACO 
in Japan, where this treatment approach will be important in 
the future. This, alongside data from other large observa-
tional studies, has the potential to advance the management 
of patients across the spectrum of obstructive respiratory 
diseases, using a personalized approach, and lead to 
improved patient outcomes.20–22,24,31
Conclusion
The TRAIT study will help to provide evidence to evaluate 
the clinical benefit of a treatable traits-based approach in 
patients with obstructive respiratory diseases. This in turn, 
will provide support for the improvement of personalized 
treatment strategies.
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